JonathonBrettCohenMD

PubMed

• 153 citations
  Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
  Radhakrishnan Ramchandren, Eva Domingo-Domenech, Antonio Rueda, Marek Trněný, Tatyana Feldman
  Journal of Clinical Oncology. 2019-05-21
• 50 citations
  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
  Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini
  Leukemia. 2021-03-03
• 670 citations
  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm p...
  Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman
  The Lancet. Oncology. 2016-09-01

Journal Articles

• Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-cell Lymphoma at an Academic Healthcare System  
  Jonathon Cohen, MD, Clinical Lymphoma, Myeloma, & Leukemia

Abstracts/Posters

• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
  Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Expert Perspectives on the Role of BTK Inhibitors in CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Aggressive Lymphomas 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all